Published in Intervirology on June 28, 2014
HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey. Med Microbiol Immunol (2015) 0.76
Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol (2007) 3.64
Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci U S A (2002) 3.46
Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol (2009) 3.13
Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res (2003) 2.37
Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) (2010) 2.33
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol (2008) 1.98
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A (2013) 1.85
Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology (2012) 1.83
Learning multiple evolutionary pathways from cross-sectional data. J Comput Biol (2005) 1.74
The human papillomavirus type 8 E2 protein induces skin tumors in transgenic mice. J Invest Dermatol (2008) 1.71
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis (2011) 1.57
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr (2006) 1.53
HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis (2013) 1.49
Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol (2009) 1.49
Mtreemix: a software package for learning and using mixture models of mutagenetic trees. Bioinformatics (2005) 1.41
Assessment of 35 children with abdominal tuberculosis. Turk J Gastroenterol (2015) 1.39
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther (2006) 1.37
Evolution of raltegravir resistance during therapy. J Antimicrob Chemother (2009) 1.33
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.32
Predicting Bevirimat resistance of HIV-1 from genotype. BMC Bioinformatics (2010) 1.30
Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. Immunol Rev (2015) 1.29
Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics (2005) 1.27
Severe human bocavirus infection, Germany. Emerg Infect Dis (2011) 1.27
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study. J Clin Microbiol (2013) 1.25
Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. J Clin Virol (2010) 1.23
Severe pneumonia and human bocavirus in adult. Emerg Infect Dis (2006) 1.22
IL-12Rβ1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS One (2011) 1.20
Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol (2010) 1.20
Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis (2005) 1.19
Detection of bocavirus DNA in nasopharyngeal aspirates of a child with bronchiolitis. J Infect (2006) 1.18
Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Ther (2007) 1.17
iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J (2011) 1.12
Tenofovir resistance and resensitization. Antimicrob Agents Chemother (2003) 1.10
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol (2003) 1.09
Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. J Infect Dis (2009) 1.07
Extraction of viral nucleic acids: comparison of five automated nucleic acid extraction platforms. J Clin Virol (2012) 1.07
Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. PLoS One (2008) 1.07
Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res (2010) 1.06
Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother (2007) 1.06
Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure. J Clin Virol (2009) 1.06
Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis (2006) 1.05
Selecting anti-HIV therapies based on a variety of genomic and clinical factors. Bioinformatics (2008) 1.03
Methods for optimizing antiviral combination therapies. Bioinformatics (2003) 1.02
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother (2011) 1.01
Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology (2013) 1.01
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS (2004) 1.00
When and how to use maraviroc in HIV-infected patients. AIDS (2009) 0.99
Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med Inform Decis Mak (2011) 0.99
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res (2010) 0.99
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. PLoS One (2010) 0.98
HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology (2012) 0.97
Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol (2006) 0.97
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Res (2011) 0.97
Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency. Clin Infect Dis (2013) 0.95
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis (2013) 0.94
High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS (2010) 0.94
Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients. J Infect (2008) 0.94
Predicting response to antiretroviral treatment by machine learning: the EuResist project. Intervirology (2012) 0.93
Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul. Med Microbiol Immunol (2013) 0.93
RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics (2013) 0.93
Basics of the virology of HIV-1 and its replication. J Clin Virol (2005) 0.93
The epidemiology and economic impact of varicella-related hospitalizations in Turkey from 2008 to 2010: a nationwide survey during the pre-vaccine era (VARICOMP study). Eur J Pediatr (2011) 0.92
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. J Thorac Oncol (2015) 0.92
Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis (2010) 0.92
Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatr Genet (2004) 0.92
Machine learning on normalized protein sequences. BMC Res Notes (2011) 0.92
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther (2010) 0.91
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology (2015) 0.91
Nintedanib: from discovery to the clinic. J Med Chem (2015) 0.91
Neuro-Behçet syndrome presenting as acute meningeal syndrome. J Infect (2005) 0.91
Novel mechanisms of HIV protease inhibitor resistance. Curr Opin HIV AIDS (2008) 0.91
Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level. Clin Vaccine Immunol (2007) 0.90
Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol (2006) 0.88
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? AIDS Res Ther (2011) 0.88
Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers. BioData Min (2011) 0.88
Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol (2005) 0.88
A novel internally controlled real-time reverse transcription-PCR assay for HIV-1 RNA targeting the pol integrase genomic region. J Virol Methods (2007) 0.88
Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients. Med Microbiol Immunol (2010) 0.88
Detection and characterization of enteroviruses and parechoviruses in healthy people living in the South of Côte d'Ivoire. J Clin Virol (2015) 0.88
Risk factors associated with older age in treatment-naive HIV-positive patients. Intervirology (2012) 0.87
Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA study 2001-2009. Intervirology (2012) 0.87
Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenet Genomics (2007) 0.87
Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res (2006) 0.87
Genotyping hepatitis B virus dual infections using population-based sequence data. J Gen Virol (2012) 0.87
Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene. Pharmacogenet Genomics (2008) 0.87
Viral etiology in hospitalized children with acute lower respiratory tract infection. Turk J Pediatr (2012) 0.86
Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. J Antimicrob Chemother (2010) 0.85
Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors. Med Microbiol Immunol (2011) 0.85